Efficacy of two times four versus continuous eight cycles of paclitaxel/bevacizumab as first-line chemotherapy in metastatic breast cancer: The Stop&Go study of the Dutch Breast Cancer Research Group (BOOG)

Research Group ◽

Metastatic Breast ◽

Breast Cancer Research ◽

First Line ◽

Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-4906-8 ◽

2018 ◽

Vol 172 (2) ◽

pp. 413-423 ◽

Cited By ~ 7

Author(s):

Anouk K. M. Claessens ◽

◽

Monique E. M. M. Bos ◽

Marta Lopez-Yurda ◽

Jeanette M. Bouma ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Research Group ◽

Metastatic Breast ◽

Breast Cancer Research ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study

British Journal of Cancer ◽

10.1038/sj.bjc.6601840 ◽

2004 ◽

Vol 90 (11) ◽

pp. 2131-2134 ◽

Cited By ~ 3

Author(s):

A C Humphreys ◽

J Dent ◽

S Rodwell ◽

S M Crawford ◽

J K Joffe ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Phase Ii ◽

Research Group ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Research ◽

Venous Infusion

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

The Lancet Oncology ◽

10.1016/s1470-2045(07)70041-4 ◽

2007 ◽

Vol 8 (3) ◽

pp. 219-225 ◽

Cited By ~ 127

Author(s):

Miguel Martín ◽

Amparo Ruiz ◽

Monserrat Muñoz ◽

Ana Balil ◽

Jesús García-Mata ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Research Group ◽

Metastatic Breast ◽

Breast Cancer Research ◽

Phase Iii ◽

Previously Treated

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG

Annals of Oncology ◽

10.1093/annonc/mdt588 ◽

2014 ◽

Vol 25 (3) ◽

pp. 599-605 ◽

Cited By ~ 28

Author(s):

C.H. Smorenburg ◽

S.M. de Groot ◽

A.E. van Leeuwen-Stok ◽

M.E. Hamaker ◽

A.N. Wymenga ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Pegylated Liposomal Doxorubicin ◽

Phase Iii ◽

First Line ◽

Phase Iii Study ◽

Epirubicin and vinorelbine versus single agent epirubicin as first line chemotherapy in metastatic breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(02)80197-6 ◽

2002 ◽

Vol 38 (11) ◽

pp. S66-S67

Author(s):

B Ejlertsen

Keyword(s):

Breast Cancer ◽

Single Agent ◽

Metastatic Breast ◽

First Line ◽

First line chemotherapy of metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdj974 ◽

2006 ◽

Vol 17 ◽

pp. v165-v168 ◽

Cited By ~ 21

Author(s):

P. Pronzato ◽

M. Rondini

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

First Line ◽

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

British Journal of Cancer ◽

10.1038/sj.bjc.6603096 ◽

2006 ◽

Vol 94 (9) ◽

pp. 1233-1236 ◽

Cited By ~ 21

Author(s):

C Pacilio ◽

◽

A Morabito ◽

F Nuzzo ◽

A Gravina ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Treatment ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Single Centre ◽

Phase Iii Trial ◽

Luminal-like metastatic breast cancer: which is the room of endocrine maintenance therapy after first line chemotherapy?

Annals of Oncology ◽

10.1093/annonc/mdv336.03 ◽

2015 ◽

Vol 26 ◽

pp. vi3

Author(s):

S. Moroso ◽

M. Bonotto ◽

L. Gerratana ◽

G. Arpino ◽

C. De Angelis ◽

...

Keyword(s):

Breast Cancer ◽

Maintenance Therapy ◽

Metastatic Breast ◽

First Line ◽

First-line chemotherapy with or without biologic agents for metastatic breast cancer

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2010.01.007 ◽

2010 ◽

Vol 76 (2) ◽

pp. 99-111 ◽

Cited By ~ 23

Author(s):

Claudia Andreetta ◽

Alessandro M. Minisini ◽

Manuela Miscoria ◽

Fabio Puglisi

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Biologic Agents ◽

First Line ◽

High dose proton pump inhibitor (PPI) in association with first line chemotherapy improves overall survival in patients with metastatic breast cancer

Frontiers in Pharmacology ◽

10.3389/conf.fphar.2014.61.00023 ◽

2014 ◽

Vol 5 ◽

Author(s):

Hu Xichun

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Proton Pump Inhibitor ◽

Proton Pump ◽

Metastatic Breast ◽

High Dose ◽

First Line ◽